Renascience Inc.

レナサイエンス

Industry: Pharmaceutical
Market: Growth
Accounting standards: Japanese GAAP
Consolidation basis: Non-consolidated

Key metrics

Revenue(thousand JPY)

Mar 2022

139,333

Mar 2023

100,545

Mar 2024

194,165

Mar 2025

132,693

Operating profit(thousand JPY)

Mar 2022

-210,839

Mar 2023

-333,870

Mar 2024

-252,335

Mar 2025

-178,827

Operating profit margin(%)

Mar 2022

-151.32

Mar 2023

-332.06

Mar 2024

-129.96

Mar 2025

-134.77

Profit before tax(thousand JPY)

Mar 2022

-253,088

Mar 2023

-333,839

Mar 2024

-256,377

Mar 2025

143,763

Profit(thousand JPY)

Mar 2022

-254,292

Mar 2023

-335,797

Mar 2024

-258,335

Mar 2025

113,427

Total assets(thousand JPY)

Mar 2022

2,438,028

Mar 2023

2,274,818

Mar 2024

2,088,833

Mar 2025

1,871,362

Cash and cash equivalents(thousand JPY)

Mar 2022

2,005,816

Mar 2023

1,831,780

Mar 2024

1,646,193

Mar 2025

1,799,816

Cash flows from operating activities(thousand JPY)

Mar 2022

-230,492

Mar 2023

-284,641

Mar 2024

-230,519

Mar 2025

-176,342

Cash flows from investing activities(thousand JPY)

Mar 2022

-296

Mar 2023

232

Mar 2024

-1,567

Mar 2025

382,147

Cash flows from financing activities(thousand JPY)

Mar 2022

1,591,662

Mar 2023

110,371

Mar 2024

46,500

Mar 2025

-52,182

Return on equity(%)

Mar 2022

Mar 2023

Mar 2024

Mar 2025

6.8

Equity ratio(%)

Mar 2022

90.3

Mar 2023

Mar 2024

76.9

Mar 2025

91.9

Earnings per share(JPY per share)

Mar 2022

-22.33

Mar 2023

-26.42

Mar 2024

-20.32

Mar 2025

8.92

Net assets per share(JPY per share)

Mar 2022

173.14

Mar 2023

146.72

Mar 2024

126.4

Mar 2025

135.32

Dividend per share(-)

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Payout ratio(-)

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.